20M Stock Chart & Stats
€0.04
>-€0.01(-2.27%)
At close: 4:00 PM EDT
€0.04
>-€0.01(-2.27%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.00
Market Cap
€14.48M
Enterprise Value€31.73M
Total Cash (Recent Filing)€1.42M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-15.92
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding457,002,000
10 Day Avg. Volume0
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-199.92
Price to Sales (P/S)433.67
P/FCF Ratio-13.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported DebtReported zero debt reduces mandatory interest and principal obligations, giving the company some balance-sheet flexibility while it develops its delivery and health technologies. This can help preserve strategic options if operating performance improves, although equity volatility remains a constraint.
Revenue GrowthThe reported revenue-growth rate indicates that commercial activity is expanding from the company’s very small base. If sustained, this trajectory could support broader product adoption and improve operating leverage over time, though the current revenue scale remains insufficient to offset losses.
Positive Gross MarginA positive trailing gross margin shows that the company’s revenue currently contributes after direct costs, providing a potential foundation for future operating improvement. At present, that contribution is overwhelmed by expenses, so durable benefit depends on scaling sales without comparable cost growth.
Bears Say
Minimal Revenue And Large LossesThe company remains at a very small commercial scale while operating and net losses are extremely large relative to revenue. This weak earnings profile limits internally generated funding, makes profitability dependent on substantial growth, and leaves little evidence of operating leverage over the next several quarters.
Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not self-funding and continues to consume cash in operations. Because free cash flow broadly tracks net loss, the losses translate into actual outflows, increasing the importance of external financing and disciplined cash management.
Equity And Margin VolatilityNegative equity in a recent annual period and recurring swings in gross profitability indicate an unstable financial base and cost structure. Even with no reported debt, this volatility can complicate capital planning, weaken resilience during continued losses, and increase reliance on equity funding.
Mountain Valley MD News
20M FAQ
What was Mountain Valley MD’s price range in the past 12 months?
Mountain Valley MD lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Mountain Valley MD’s market cap?
Mountain Valley MD’s market cap is €14.48M.
When is Mountain Valley MD’s upcoming earnings report date?
Mountain Valley MD’s upcoming earnings report date is Nov 26, 2026 which is in 34 days.
How were Mountain Valley MD’s earnings last quarter?
Mountain Valley MD released its earnings results on Jul 28, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Mountain Valley MD overvalued?
According to Wall Street analysts Mountain Valley MD’s price is currently Overvalued.
Does Mountain Valley MD pay dividends?
Mountain Valley MD does not currently pay dividends.
What is Mountain Valley MD’s EPS estimate?
Mountain Valley MD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mountain Valley MD have?
Mountain Valley MD has 457,002,000 shares outstanding.
What happened to Mountain Valley MD’s price movement after its last earnings report?
Mountain Valley MD reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went up 16.667%.
Which hedge fund is a major shareholder of Mountain Valley MD?
Currently, no hedge funds are holding shares in DE:20M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mountain Valley MD
The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksome™ and Quicksol™. The Quicksome™ patented technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into product formats that, if successfully commercialized, could enhance the efficacy of molecule delivery across a variety of nutraceutical product applications. The Quicksol™ patented is a solubilization technology, which has been developed to provide solubilized drug delivery options. The company was founded on March 8, 2005 and is headquartered in Vaughan, Canada.